BlossomHill Therapeutics, Inc. (Nasdaq: BLSM) presented preclinical data on its investigational pan-KRAS inhibitor, BH-501284, at the American Association for Cancer ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE